MustGrow Announces Record Q3-2025 Results

Core Insights - MustGrow Biologics Corp. reported its operating and financial results for Q3-2025, highlighting a significant increase in sales revenue and gross profit margin compared to the previous quarter [2][3][6]. Financial Performance - The company recorded sales revenue of $0.8 million in Q3-2025, a notable increase from no revenue in Q3-2024 [6]. - Gross profit amounted to $180,555, resulting in a gross profit margin of 22.9% in Q3-2025, up from 20.9% in Q2-2025 [6]. - Cash and equivalents on hand as of September 30, 2025, were $3.3 million, with inventory valued at $1.9 million [6]. Market Context - The third calendar quarter is typically a low revenue period for Canadian agriculture due to the harvesting season, which impacts farmers' purchasing behavior [3]. - MustGrow anticipates stronger sales in Q4-2025 and Q1-2026 as farmers prepare for the 2026 growing season [3]. Business Strategy - The company is focused on capital allocation to drive revenue growth in its NexusBioAg Canadian sales and distribution business, as well as its TerraSanteTM biofertility product sales in the U.S. [3]. - MustGrow aims to expand its intellectual property portfolio, which includes approximately 109 patents, and enhance shareholder value through the commercialization of its proprietary products [5].